A20, a negative regulator of NF-κB signaling [37], and IL10, which mediates immune inhibition and cell survival downstream the CD5 signaling [10, 11], did not show differential expression of mRNAs between CD5+ and CD5− DLBCL patients. The gene discussed is CD5; the disease is diffuse large B-cell lymphoma.